A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

NCT04281472 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
322
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

argenx